Brief: Nanobiotix Announces Red Journal Publication Of Preclinical Data Showing Radioenhancer NBTXR3 May “Reprogram” The Tumor Microenvironment To Overcome Anti-PD-1 Resistance And Evoke Abscopal Effect
28/09/2021 21:25
Sept 28 (Reuters) - Nanobiotix SA NANOB.PA :
* NANOBIOTIX ANNOUNCES RED JOURNAL PUBLICATION OF
PRECLINICAL DATA
SHOWING RADIOENHANCER NBTXR3 MAY “REPROGRAM” THE TUMOR
MICROENVIRONMENT TO OVERCOME ANTI-PD-1 RESISTANCE AND EVOKE
ABSCOPAL EFFECT
Source text for Eikon: ID:nBw1D7gf7a
Further company coverage: NANOB.PA
Recent news on Nanobiotix SA
See all newsBrief: Nanobiotix S.A. H1 Net Income EUR -34.3 Million
France's Nanobiotix H1 net loss widens on lower revenue, absence of 2025 one-off gain
Brief: Nanobiotix Reports Encouraging Full Phase 1 Results For Lung Cancer Drug JNJ-1900
Brief: Nanobiotix Q1 Cash And Cash Equivalents Of €42.1 Mln
Brief: NANOBIOTIX Announces Closing Of Global Offering